Literature DB >> 8092782

Mastitis today: incidence, prevention and treatment.

S Jonsson1, M O Pulkkinen.   

Abstract

The study concerned 664 women of South-West Finland, and they were studied 5-12 weeks after delivery. The total frequency of mastitis in this population was much higher than generally reported in literature, 24% as opposed to 3%. The frequency of mastitis was similar among nulli- and multiparous women. The diagnosis was based on the judgement of midwives of physicians. If a multiparous woman has had mastitis during a previous puerperium, the probability of mastitis during a subsequent puerperium is threefold. The type of skin, its reaction of the sun, allergies, rashes, getting cold and oxytocin medication during delivery did nto affect the incidence of mastitis. Mothers under 21 and over 35 years of age had a decreased incidence (P = 0.034) of mastitis. If the women had sore nipples, the frequency increased (P = 0.003). Prophylaxis, by means of physical training, neither decreased nor increased the frequency of puerperal mastitis. The treatment advised by midwives and physicians was primarily conservative, but 38% received antibiotics; some of the antibiotics were not effective against staphylococcal infection.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8092782

Source DB:  PubMed          Journal:  Ann Chir Gynaecol Suppl        ISSN: 0355-9874


  20 in total

Review 1.  Antibiotics and breast-feeding: a critical review of the literature.

Authors:  Allison M Chung; Michael D Reed; Jeffrey L Blumer
Journal:  Paediatr Drugs       Date:  2002       Impact factor: 3.022

Review 2.  Mastitis therapy and antimicrobial susceptibility: a multispecies review with a focus on antibiotic treatment of mastitis in dairy cattle.

Authors:  John Barlow
Journal:  J Mammary Gland Biol Neoplasia       Date:  2011-10-09       Impact factor: 2.673

Review 3.  The microbiology and treatment of human mastitis.

Authors:  Angeliki Angelopoulou; Des Field; C Anthony Ryan; Catherine Stanton; Colin Hill; R Paul Ross
Journal:  Med Microbiol Immunol       Date:  2018-01-19       Impact factor: 3.402

4.  Mastitis and immunological factors in breast milk of lactating women in Malawi.

Authors:  R D Semba; N Kumwenda; T E Taha; D R Hoover; Y Lan; W Eisinger; L Mtimavalye; R Broadhead; P G Miotti; L Van Der Hoeven; J D Chiphangwi
Journal:  Clin Diagn Lab Immunol       Date:  1999-09

5.  Extensive in vivo human milk peptidomics reveals specific proteolysis yielding protective antimicrobial peptides.

Authors:  David C Dallas; Andres Guerrero; Nora Khaldi; Patricia A Castillo; William F Martin; Jennifer T Smilowitz; Charles L Bevins; Daniela Barile; J Bruce German; Carlito B Lebrilla
Journal:  J Proteome Res       Date:  2013-04-24       Impact factor: 4.466

6.  Experimental autoimmune breast failure: a model for lactation insufficiency, postnatal nutritional deprivation, and prophylactic breast cancer vaccination.

Authors:  Pavani Kesaraju; Ritika Jaini; Justin M Johnson; Cengiz Z Altuntas; Jessica J Gruden; Cagri Sakalar; Vincent K Tuohy
Journal:  Am J Pathol       Date:  2012-09       Impact factor: 4.307

7.  Puerperal mastitis: a reproductive event of importance affecting anti-mucin antibody levels and ovarian cancer risk.

Authors:  Daniel W Cramer; Kristina Williams; Allison F Vitonis; Hidemi S Yamamoto; Alison Stuebe; William R Welch; Linda Titus; Raina N Fichorova
Journal:  Cancer Causes Control       Date:  2013-08-08       Impact factor: 2.506

8.  ASSOCIATION OF HIV WITH BREAST ABSCESS AND ALTERED MICROBIAL SUSCEPTIBILITY PATTERNS.

Authors:  Bernard Kapatamoyo; Benjamin Andrews; Kasonde Bowa
Journal:  Med J Zambia       Date:  2010

9.  Re-examination of old truths: replication of a study to measure the incidence of lactational mastitis in breastfeeding women.

Authors:  Linda J Kvist
Journal:  Int Breastfeed J       Date:  2013-04-20       Impact factor: 3.461

10.  Colostrum TGF-beta-1 associates with the duration of breast-feeding.

Authors:  Erkki Savilahti; Kristiina M Saarinen
Journal:  Eur J Nutr       Date:  2007-05-11       Impact factor: 4.865

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.